Zacks Investment Research downgraded shares of Newron Pharmaceuticals (OTCMKTS:NWPHF) from a hold rating to a sell rating in a research note released on Tuesday.
According to Zacks, “Newron Pharmaceuticals SpA is a biopharmaceutical company. It focuses on the discovery and development of drugs for the treatment of central nervous system disorders and pain primarily in Italy and internationally. Newron Pharmaceuticals SpA is headquartered in Bresso, Italy. “
Shares of NWPHF stock opened at $7.98 on Tuesday. The stock has a market capitalization of $142.36 million, a PE ratio of -22.17 and a beta of 0.44. Newron Pharmaceuticals has a one year low of $10.95 and a one year high of $11.00.
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease.
Featured Article: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Newron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.